| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Scientific Officer | Director
1 company
Jonathan Adam Feldschuh is Chief Scientific Officer at DXR. Jonathan Adam Feldschuh's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $702K at current prices.
Net of sales, the DXR filings show accumulation of 30,806 shares.
Jonathan Adam Feldschuh has 6 Form 4 filings on record from March 2018 to June 2026, all as Chief Scientific Officer at Daxor (DXR), 2018–2026.
The 6 reported transactions were 2 open-market purchases, 2 option or other derivative awards, 1 stock award and 1 open-market sale.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $358K.
The only open-market sale was 19,194 shares of DXR at an average $18.63 on March 15, 2018, about $358K.